EULAR® 2024 Insights
Clinical Implications of DISSOLVE I Phase 3, Double-Blind, Placebo-Controlled Clinical Trial for Gout Patients
By
EULAR® 2024 Insights
FEATURING
Alan Kivitz
By
EULAR® 2024 Insights
FEATURING
Alan Kivitz
Comments 0
Login to view comments.
Click here to Login
